The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics ... modulate muscarinic receptors by targeting the acetylcholine binding site have been largely unsuccessful ...

such as the 5-HT 1A receptor, are considered to mediate the ability of antipsychotic drugs to enhance cognition. On the other hand, treatment with some atypical agents, such as risperidone ...

The WCNDD approach uses positive allosteric modulators to target receptors at sites outside their main ligand-binding pockets ... with Efficacy in Preclinical Antipsychotic and Cognition Models ...

Distinct pharmacologic profiles, especially actions on 5-hydroxytryptamine (5-HT) receptor subtypes, may contribute to the advantage of atypical antipsychotics in terms of adverse effects.